First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression.
Claudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, Giorgia Russo, Serena Maria Boccia, Adriana Ionelia Apostol, Ilary Ruscito, Luca Romano, Christian Marth, Anna Fagotti, Francesca De Felice
Crit Rev Oncol Hematol 224 105383
摘要
摘要
INTRODUCTION: Despite response to up-front treatment, patients with ovarian cancer remain at high risk of recurrence, with poor survival. Immunotherapy plus chemotherapy, alone or in combination with poly(ADP-ribose) polymerase inhibitors (PARPi) or VEGF inhibitors, has been investigated in ovarian cancer, with heterogeneous results. METHODS: A meta-analysis of randomized phase III trials was conducted. PubMed, EMBASE, ClinicalTrials.gov, and congress proceedings were systematically searched. Two comparisons were performed: i) mono-immunotherapy throughout and the relative control arm; ii) immunotherapy plus PARPi and the relative control arm. The primary endpoint was the progression-free survival (PFS) and was analyzed in the overall population and by bevacizumab use, BRCA/homologous recombination deficiency (HRD) status, and PD-L1 expression. RESULTS: Six trials, involving 6465 patients, were analyzed. In the overall population, immunotherapy did not affect PFS, alone [Hazard ratio (HR) 0.94, 95% Confidence Interval (CI) 0.85-1.05] or with PARPi (HR 0.83, 95% CI 0.62-1.12). Potential benefits are suggested in selected populations. Immunotherapy plus PARPi and bevacizumab significantly improved PFS (HR 0.71, 95% CI 0.58-0.85). A PFS benefit was observed in the HRD-positive, BRCA wild-type and PD-L1-negative populations receiving immunotherapy plus PARPi (HR 0.71, 95% CI 0.52-0.97 and HR 0.72, 95% CI 0.57-0.91, respectively) compared to control groups. Mono-immunotherapy showed a slight advantage in HRD-negative patients (HR 0.87, 95% CI 0.78-0.98). CONCLUSION: In first-line treatment of advanced ovarian cancer, immunotherapy ± PARPi does not provide PFS benefits in unselected patients. However, efficacy signals in specific subgroups support the need for biomarker-driven strategies and optimized trials.
KM 提取结果
0 个 Figure · 0 个 KM 面板